The effects of staphylococcal protein A on human lymphokine-activated killer cell induction
Staphylococcal protein A (Cowan strain; SpA), a biologically active molecule capable of inducing augmented natural killer (NK) cell cytotoxicity, was studied in regard to its effects on lymphokine-activated killer (LAK) cell development. SpA, when co-cultured with interleukin-2 (IL-2) for 4 days, si...
Uloženo v:
| Vydáno v: | Cancer immunology, immunotherapy : CII Ročník 33; číslo 2; s. 97 |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Germany
01.03.1991
|
| Témata: | |
| ISSN: | 0340-7004 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Staphylococcal protein A (Cowan strain; SpA), a biologically active molecule capable of inducing augmented natural killer (NK) cell cytotoxicity, was studied in regard to its effects on lymphokine-activated killer (LAK) cell development. SpA, when co-cultured with interleukin-2 (IL-2) for 4 days, significantly augmented both LAK activity against NK-resistant M14 (melanoma) target cells and DNA synthesis of peripheral blood mononuclear cells (PBMC). This enhancement occurred with SpA concentrations of 1-100 micrograms/ml in a dose-dependent fashion; concentrations above 100 micrograms/ml were no more effective. When SpA (10 micrograms/ml) was added to PBMC cultures with various IL-2 concentrations, cytotoxicity was increased over controls with IL-2 alone. The peak cytotoxic effect reached a plateau at 80 U/ml IL-2. SpA alone induced early (day 1) cytotoxicity, which rapidly declined. SpA alone did not induce PBMC proliferation but it did increase expression of CD25 (Tac), IL-2 receptor alpha chain, on CD56(Leu19)-positive and -negative cells. The potentiating effect of SpA was significantly enhanced in serum-free medium. If either human AB serum or human IgG was added to cultures SpA-enhanced LAK cytotoxicity was diminished. The addition of anti-interferon gamma (anti-IFN gamma) antibody, but not anti-IFN alpha, inhibited (SpA+IL-2)-induced cytotoxicity, indicating that IFN gamma is partially responsible for the additive cytotoxic effect. |
|---|---|
| AbstractList | Staphylococcal protein A (Cowan strain; SpA), a biologically active molecule capable of inducing augmented natural killer (NK) cell cytotoxicity, was studied in regard to its effects on lymphokine-activated killer (LAK) cell development. SpA, when co-cultured with interleukin-2 (IL-2) for 4 days, significantly augmented both LAK activity against NK-resistant M14 (melanoma) target cells and DNA synthesis of peripheral blood mononuclear cells (PBMC). This enhancement occurred with SpA concentrations of 1-100 micrograms/ml in a dose-dependent fashion; concentrations above 100 micrograms/ml were no more effective. When SpA (10 micrograms/ml) was added to PBMC cultures with various IL-2 concentrations, cytotoxicity was increased over controls with IL-2 alone. The peak cytotoxic effect reached a plateau at 80 U/ml IL-2. SpA alone induced early (day 1) cytotoxicity, which rapidly declined. SpA alone did not induce PBMC proliferation but it did increase expression of CD25 (Tac), IL-2 receptor alpha chain, on CD56(Leu19)-positive and -negative cells. The potentiating effect of SpA was significantly enhanced in serum-free medium. If either human AB serum or human IgG was added to cultures SpA-enhanced LAK cytotoxicity was diminished. The addition of anti-interferon gamma (anti-IFN gamma) antibody, but not anti-IFN alpha, inhibited (SpA+IL-2)-induced cytotoxicity, indicating that IFN gamma is partially responsible for the additive cytotoxic effect. Staphylococcal protein A (Cowan strain; SpA), a biologically active molecule capable of inducing augmented natural killer (NK) cell cytotoxicity, was studied in regard to its effects on lymphokine-activated killer (LAK) cell development. SpA, when co-cultured with interleukin-2 (IL-2) for 4 days, significantly augmented both LAK activity against NK-resistant M14 (melanoma) target cells and DNA synthesis of peripheral blood mononuclear cells (PBMC). This enhancement occurred with SpA concentrations of 1-100 micrograms/ml in a dose-dependent fashion; concentrations above 100 micrograms/ml were no more effective. When SpA (10 micrograms/ml) was added to PBMC cultures with various IL-2 concentrations, cytotoxicity was increased over controls with IL-2 alone. The peak cytotoxic effect reached a plateau at 80 U/ml IL-2. SpA alone induced early (day 1) cytotoxicity, which rapidly declined. SpA alone did not induce PBMC proliferation but it did increase expression of CD25 (Tac), IL-2 receptor alpha chain, on CD56(Leu19)-positive and -negative cells. The potentiating effect of SpA was significantly enhanced in serum-free medium. If either human AB serum or human IgG was added to cultures SpA-enhanced LAK cytotoxicity was diminished. The addition of anti-interferon gamma (anti-IFN gamma) antibody, but not anti-IFN alpha, inhibited (SpA+IL-2)-induced cytotoxicity, indicating that IFN gamma is partially responsible for the additive cytotoxic effect.Staphylococcal protein A (Cowan strain; SpA), a biologically active molecule capable of inducing augmented natural killer (NK) cell cytotoxicity, was studied in regard to its effects on lymphokine-activated killer (LAK) cell development. SpA, when co-cultured with interleukin-2 (IL-2) for 4 days, significantly augmented both LAK activity against NK-resistant M14 (melanoma) target cells and DNA synthesis of peripheral blood mononuclear cells (PBMC). This enhancement occurred with SpA concentrations of 1-100 micrograms/ml in a dose-dependent fashion; concentrations above 100 micrograms/ml were no more effective. When SpA (10 micrograms/ml) was added to PBMC cultures with various IL-2 concentrations, cytotoxicity was increased over controls with IL-2 alone. The peak cytotoxic effect reached a plateau at 80 U/ml IL-2. SpA alone induced early (day 1) cytotoxicity, which rapidly declined. SpA alone did not induce PBMC proliferation but it did increase expression of CD25 (Tac), IL-2 receptor alpha chain, on CD56(Leu19)-positive and -negative cells. The potentiating effect of SpA was significantly enhanced in serum-free medium. If either human AB serum or human IgG was added to cultures SpA-enhanced LAK cytotoxicity was diminished. The addition of anti-interferon gamma (anti-IFN gamma) antibody, but not anti-IFN alpha, inhibited (SpA+IL-2)-induced cytotoxicity, indicating that IFN gamma is partially responsible for the additive cytotoxic effect. |
| Author | Shau, H Lindemann, R A Singh, K P Gupta, R K |
| Author_xml | – sequence: 1 givenname: R A surname: Lindemann fullname: Lindemann, R A organization: Department of Surgery/Oncology, UCLA School of Medicine – sequence: 2 givenname: K P surname: Singh fullname: Singh, K P – sequence: 3 givenname: H surname: Shau fullname: Shau, H – sequence: 4 givenname: R K surname: Gupta fullname: Gupta, R K |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/1709823$$D View this record in MEDLINE/PubMed |
| BookMark | eNotkDFPwzAUhD0UlbawsCN5Ygs8J05ij6WigFSJpUwMkes8K6GOHWIHqf-eVHS6k-7T6XRLMnPeISF3DB4ZQPn0vAVW8jTPihlZQMYhKQH4NVmG8D2ZFKSckzkrQYo0W5CvfYMUjUEdA_WGhqj65mS99lorS_vBR2wdXVPvaDN2ylF76vrGH1uHidKx_VURa3psrcWBarSWtq4ep8C7G3JllA14e9EV-dy-7Ddvye7j9X2z3iWaQxYT5IVEVKnSUhQKjDGcCagLKWQuDJSHPNOItcxEwVghpRGGK42gaiFMUbJ0RR7-e6e1PyOGWHVtOE9RDv0YKgF5CSk_g_cXcDx0WFf90HZqOFWXN9I_87thPg |
| CitedBy_id | crossref_primary_10_3109_08923979309019729 crossref_primary_10_1016_S0165_2478_98_00102_3 crossref_primary_10_1007_BF02815537 crossref_primary_10_1111_j_1440_1827_1994_tb02948_x crossref_primary_10_1111_j_1600_0897_1995_tb00904_x |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1007/BF01742536 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 1709823 |
| Genre | Research Support, U.S. Gov't, P.H.S Journal Article |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: CA-16042 – fundername: NIDCR NIH HHS grantid: 1 R29 DE09 174-01 |
| GroupedDBID | --- -53 -56 -5G -BR -EM -Y2 -~C .55 .86 .VR 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 28- 29B 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6J9 6NX 78A 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AAHNG AAIAL AAJKR AAJSJ AAKKN AANXM AANZL AARHV AARTL AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABEEZ ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMOR ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACACY ACBXY ACGFS ACHSB ACHVE ACHXU ACIHN ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACREN ACUDM ACULB ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYOE ADZKW AEAQA AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFGXO AFJLC AFKRA AFLOW AFQWF AFWTZ AFYQB AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBNVY BBWZM BDATZ BENPR BGNMA BHPHI BPHCQ BVXVI C24 C6C CAG CCPQU CGR COF CSCUP CUY CVF DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS ECM EIF EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GROUPED_DOAJ GRRUI GXS H13 HCIFZ HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IH2 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LK8 LLZTM M1P M4Y M7P MA- N2Q N9A NB0 NDZJH NPM NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPM RPX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SBL SCLPG SDE SDH SDM SHX SISQX SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UDS UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 X7M YLTOR Z45 Z7U Z82 Z84 Z87 Z8O Z8V Z8Y Z91 ZGI ZMTXR ZOVNA ~EX ~KM 7X8 ADHKG AGQPQ |
| ID | FETCH-LOGICAL-c403t-e469eea2ac986a0fff4180d698958f07b53ceed938611699f8f4ace0ad88f6712 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 5 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=10_1007_BF01742536&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0340-7004 |
| IngestDate | Sun Nov 09 10:40:39 EST 2025 Wed Feb 19 02:07:00 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c403t-e469eea2ac986a0fff4180d698958f07b53ceed938611699f8f4ace0ad88f6712 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/11038565 |
| PMID | 1709823 |
| PQID | 80570241 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_80570241 pubmed_primary_1709823 |
| PublicationCentury | 1900 |
| PublicationDate | 1991-03-00 |
| PublicationDateYYYYMMDD | 1991-03-01 |
| PublicationDate_xml | – month: 03 year: 1991 text: 1991-03-00 |
| PublicationDecade | 1990 |
| PublicationPlace | Germany |
| PublicationPlace_xml | – name: Germany |
| PublicationTitle | Cancer immunology, immunotherapy : CII |
| PublicationTitleAlternate | Cancer Immunol Immunother |
| PublicationYear | 1991 |
| SSID | ssj0042099 ssj0001254 |
| Score | 1.390142 |
| Snippet | Staphylococcal protein A (Cowan strain; SpA), a biologically active molecule capable of inducing augmented natural killer (NK) cell cytotoxicity, was studied... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 97 |
| SubjectTerms | Antigens, Differentiation, T-Lymphocyte - analysis CD56 Antigen Drug Synergism Flow Cytometry Humans Immunoglobulin G - physiology Interferon-gamma - physiology Interleukin-2 - pharmacology Killer Cells, Lymphokine-Activated - drug effects Killer Cells, Lymphokine-Activated - immunology Staphylococcal Protein A - pharmacology |
| Title | The effects of staphylococcal protein A on human lymphokine-activated killer cell induction |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/1709823 https://www.proquest.com/docview/80570241 |
| Volume | 33 |
| WOSCitedRecordID | wos10_1007_BF01742536&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEB6qFfHiu1ifOXgNZjfZbBYEKWLxYEsPKgUPS5pNoFh2q60F_72TfSAexIOXhRwCYXYy3zeZF8Cl0S4W0kRo_XhEhc5CqoUwlIdMZExObBUueH6Ih0M1HiejFlw3tTA-rbKxiaWhzgrj38ivFBILxJPgZv5G_cwoH1utB2isQZsjkfE6HY-_e4UjdItmIXyFaBlQ8Al0uP7ZqRRpeRhx-TvLLNGmv_O_c-7Cds0ySa9Siz1o2XwfNgd1HP0AXlA7SJ3KQQpHkCKiuBHXChT1jJTNG6Y56ZEiJ-UUPzL7xN9evOJu6kshVkhRM_JaFhIS__hP0LevGtEewlP_7vH2ntZjFqgRjC-pRQ_ZWh1qkyipmXNOBIplfrJkpByLJxH3SJpwJYNAJolTTmhjmc6UcjIOwg6s50Vuj4BMogQdRsms4M639puEPNISzYg2CIrSdOGiEVqKauyPp3NbfCzSRmxd6FRyT-dVt400iFmiQn7859YT2KryuHyC2Cm0Hd5fewYbZrWcLt7PS-XA73A0-AJK0sLW |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effects+of+staphylococcal+protein+A+on+human+lymphokine-activated+killer+cell+induction&rft.jtitle=Cancer+immunology%2C+immunotherapy+%3A+CII&rft.au=Lindemann%2C+R+A&rft.au=Singh%2C+K+P&rft.au=Shau%2C+H&rft.au=Gupta%2C+R+K&rft.date=1991-03-01&rft.issn=0340-7004&rft.volume=33&rft.issue=2&rft.spage=97&rft_id=info:doi/10.1007%2FBF01742536&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0340-7004&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0340-7004&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0340-7004&client=summon |